CliffBio
small molecule

LORBRENA

LORLATINIB

Loss of exclusivityOctober 2038latest FDA-listed patent expiry
CompanyPfizer →See this company's full patent-cliff portfolio

Drug detail

Brand nameLORBRENA
Active ingredientLORLATINIB
Strength25MG
Dosage formTABLET
RouteORAL
ModalitySmall molecule
FDA approvalNovember 2018
Marketing statusRX

Listed patents

PatentExpiresType
11299500October 2038substance
10420749July 2036substance, product
11020376July 2036product
8680111March 2033substance, product

Regulatory exclusivity

CodeExpires
ODE-349March 2028

More from Pfizer

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

LORBRENA patent cliff — loss of exclusivity October 2038 | CliffBio